Skip to main content

Gout

    Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting. COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al. C-…
    RT @RichardPAConway: Dr Dehlin presents Swedish data showing ⬆️ risk of all cause mortality (HR: 1.08 (95% CL: 1.05-
    2 years 10 months ago
    Dr Dehlin presents Swedish data showing ⬆️ risk of all cause mortality (HR: 1.08 (95% CL: 1.05-1.11) and most comorbidities but a ⬇️ risk dementia in gout 0.68 (0.60-0.77) @RheumNow #EULAR2021 Abstr#OP0208 https://t.co/0ojpSbfIHM
    RT @Janetbirdope: My toe hurts & it’s a killer! Gout is related to ⬆️comorbidities - clusters incl no comorbid
    2 years 10 months ago
    My toe hurts & it’s a killer! Gout is related to ⬆️comorbidities - clusters incl no comorbidities to worse outcomes if CRF in gout. HTN⬆️ Gout has SNIPs assoc w HTN & May be the cause. Incident Gout assoc with Acute coronary syndrome OP0193 OP0192 #EULAR2021 @RheumNow @eular_org https://t.co/CS6o0T1FL2
    Novartis announced that Cosentyx (secukinumab) has received FDA approval for treatment of children and adolescents with
    2 years 10 months ago
    Novartis announced that Cosentyx (secukinumab) has received FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis #EULAR2021 https://t.co/JlkmjLwqQ8
    Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual…